Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0382 SAD in Overweight/Obese Japanese or Chinese Subjects
NCT03385369Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jan 2018
- Primary completion
- Apr 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cotadutide in obesity and Overweight (6 arms), sponsored by MedImmune. Primary endpoints: Treatment-emergent Adverse Events, Adverse Events of Special Interest and 3 more. Started Jan 2018; status: completed.
02
Drugs
cotadutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03385369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385369.